Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Videos|October 21, 2020
Expert Update on Lp(a): Dr Patrick Moriarty Explains the Next CVD Target
Author(s)Grace Halsey
Elevated lipoprotein A is a genetically determined independent risk factor for CVD, affecting up to 30% of the population. Phase 3 trials for the first treatment are underway.
Advertisement
________________________________________________________________
Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.
His research activities include atherosclerosis, lipid apheresis, vascular inflamation and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease.
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement